Pfizer Inc. has announced the completion of a global (ex-China) licensing agreement with 3SBio Inc. for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. Developed using 3SBio’s proprietary CLF2 platform, SSGJ-707 represents a promising innovation in immuno-oncology.
Under the agreement, Pfizer gains exclusive rights to develop, manufacture, and commercialize SSGJ-707 outside China. This move further strengthens Pfizer’s oncology pipeline and reinforces its leadership in cutting-edge cancer research.
“We’re eager to apply our expertise to accelerate the SSGJ-707 program, including exploring novel combination therapies across several major tumor types,” said Dr. Chris Boshoff, Chief Scientific Officer and President of R&D at Pfizer. “This candidate aligns with our strategic focus in oncology, enhancing our bispecific and antibody-drug conjugate portfolios.”
SSGJ-707 is currently being evaluated in multiple clinical trials in China, targeting non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Interim Phase 2 data presented at the 2024 ASCO Annual Meeting showed encouraging safety and efficacy results in advanced NSCLC.
Looking ahead, Pfizer will produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas. Global Phase 3 trials, with an initial focus on NSCLC and other solid tumors, are slated to begin enrollment in the U.S.
As part of the deal, 3SBio will receive an upfront payment of $1.25 billion, along with a $100 million equity investment from Pfizer. The agreement also includes an option for Pfizer to expand its license to include China, which could lead to additional option payments of up to $150 million.